Compare · BSX vs KRMD
BSX vs KRMD
Side-by-side comparison of Boston Scientific Corporation (BSX) and KORU Medical Systems Inc. (KRMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and KRMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $84.93B, about 460.0x KRMD ($184.7M).
- Over the past year, BSX is down 44.4% and KRMD is up 44.4% - KRMD leads by 88.8 points.
- Both names hit the wire about 3 times in the past 4 weeks.
- BSX has more recent analyst coverage (25 ratings vs 6 for KRMD).
- Company
- Boston Scientific Corporation
- KORU Medical Systems Inc.
- Price
- $57.16-2.20%
- $3.97-2.22%
- Market cap
- $84.93B
- $184.7M
- 1M return
- -9.16%
- -6.37%
- 1Y return
- -44.42%
- +44.36%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 3
- 3
- Recent ratings
- 25
- 6
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
KORU Medical Systems Inc.
Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
Latest BSX
- Data at Heart Rhythm 2026 highlight key Boston Scientific therapies
- Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Boston Scientific announces results for first quarter 2026
- SEC Form EFFECT filed by Boston Scientific Corporation
- SEC Form 424B3 filed by Boston Scientific Corporation
- Boston Scientific downgraded by Raymond James with a new price target
- Boston Scientific announces conference call discussing first quarter 2026 results
- Amendment: SEC Form S-4/A filed by Boston Scientific Corporation
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
Latest KRMD
- KORU Medical Systems to Report First Quarter 2026 Financial Results on May 6, 2026
- SEC Form DEF 14A filed by KORU Medical Systems Inc.
- Amendment: SEC Form 4 filed by Manko Joseph M. Jr.
- KORU Medical Systems Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- SEC Form 4 filed by Wholihan Edward
- SEC Form 4 filed by Cascella Robert
- SEC Form 4 filed by French Donna
- SEC Form 4 filed by Matin Shahriar
- SEC Form 4 filed by Fletcher R John
- SEC Form 4 filed by Manko Joseph M. Jr.